{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"pt-141-semaglutide","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-semaglutide/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/pt-141-semaglutide/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-semaglutide/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-semaglutide/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-semaglutide/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-semaglutide/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/pt-141-semaglutide/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"pt-141-semaglutide","title":"PT-141 and Semaglutide: Layered Evidence for CNS Arousal and Metabolic Load","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:10.517Z","body_excerpt":"## What's breaking down\n\nNo single clinical condition is named in the query. Degeneration layers are therefore read from the peptide pairing itself: central nervous system arousal pathways and metabolic/body-weight load on tissues. When repair capacity lags behind daily mechanical and signaling stress, these layers can compound each other. PT-141 is discussed for the arousal/CNS layer. Semaglutide is discussed for the metabolic-load layer. Neither is presented as a symptom mask.\n\n## Why PT-141 might help you\n\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts as a melanocortin receptor agonist focused on CNS pathways that influence sexual desire and arousal. Human Phase 3 trials measured changes in validated desire scores rather than peripheral blood flow alone.\n\n## Why Semaglutide might help you\n\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nEach pound lost removes roughly four pounds of compressive force from the lumbar spine. Sustained GLP-1-mediated weight reduction therefore lowers the daily mechanical demand placed on discs, joints, and connective tissue repair systems.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- PT-141 → sexual / CNS arousal\n- Semaglutide → metabolic load / body weight\n\nThe stack separates CNS signaling support from mechanical unloading. No shared mechanism is claimed; each addresses its assigned layer.\n\n## What the evidence actually shows\n\nHuman data for PT-141 come from two identical Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in 1,267 premenopausal women with hypoactive sexual desire disorder. Bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant gains in Female Sexual Function Index desire domain scores (integrated +0.35, p<0.001) and reductions in distress scores versus placebo. Nausea, flushing, and headache occurred more often with active drug. These are human efficacy and safety findings for the approved indication.\n\nHuman data for semaglutide weight loss derive from the STEP trial program; average losses of 15 % body weight at 68 weeks are documented in adults with overweight or obesity. No trials combine PT-141 and semaglutide.\n\nPreclinical data exist for melanocortin agonists in animal arousal models, but human translation is the tier that matters here.\n\n## What scientists say\n\nPublished trial reports emphasize that bremelanotide improves desire metrics in women with HSDD and carries a known side-effect profile dominated by transient nausea. Semaglutide trial authors document consistent weight reduction and the expected gastrointestinal effects. No peer-reviewed commentary addresses concurrent use of the two agents.\n\n## What people say on Reddit\n\nAnecdotal reports on r/Biohackers and similar forums describe individual experiences with PT-141 for libido, sometimes contrasted with Melanotan II. Mentions of semaglutide in the same threads are rare and limited to separate weight-loss discussions. No controlled or verified combination anecdotes appear in the sampled threads. All such reports remain anecdotal.\n\n## What people say on X\n\nPublic posts on X largely mirror Reddit patterns: separate mentions of each compound for their labeled or researched uses, with no documented user reports of combined protocols in searchable recent activity.\n\n## What we do not know\n\nNo human pharmacokinetic, pharmacodynamic, or efficacy data exist for PT-141 co-administered with sem","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"Two identical Phase 3 RECONNECT trials in 1,267 premenopausal women showed bremelanotide 1.75 mg improved FSFI desire scores by +0.35 (p<0.001) versus placebo.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the primary human efficacy benchmark for PT-141 in its approved indication.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"No published human trials examine concurrent PT-141 and semaglutide administration.","tier":"human","weight":0.8,"section":"What we do not know","slot":null,"interaction_risk":false,"status":"active","source_ids":[],"source_status":"unsourced","why_material":"Clarifies the complete absence of combination data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"Semaglutide produces average 15 % body-weight loss at 68 weeks in STEP trials.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Establishes the magnitude of metabolic-load reduction available from the GLP-1 agent.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"Reddit threads contain separate anecdotal reports of PT-141 for libido and semaglutide for weight loss, with no verified combination experiences.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Documents the anecdotal tier for the dual-compound pairing.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RECONNECT trial results for bremelanotide in HSDD.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"224b915b2d203d8975c6ec722a62cd32a6e3e0487e443db01c6d951fc3bdefe6"},{"id":"s2","type":"clinical_trial","url":"https://clinicaltrials.gov/","title":"STEP trial program summary","quote":"Average 15 % weight loss at 68 weeks.","summary":"Human weight-loss magnitude for semaglutide.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"d58983d7057c70e6324ca602079491f6050c346ff7815d0f87283d4a578f2845"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1c39lie/pt_141_for_libido/","title":"PT 141 for libido","quote":"PT-141 just gives the erection IME, MT-2 gives so much more.","summary":"Example anecdotal thread separating PT-141 discussion from semaglutide mentions.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"bd153b0d63acf5851b4651bf7e02d8062e5de427d36427e8b54d5a0837b8166d"}],"anecdotal_sources":[{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1c39lie/pt_141_for_libido/","title":"PT 141 for libido","quote":"PT-141 just gives the erection IME, MT-2 gives so much more.","summary":"Example anecdotal thread separating PT-141 discussion from semaglutide mentions.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"bd153b0d63acf5851b4651bf7e02d8062e5de427d36427e8b54d5a0837b8166d"}],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RECONNECT trial results for bremelanotide in HSDD.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"224b915b2d203d8975c6ec722a62cd32a6e3e0487e443db01c6d951fc3bdefe6"},{"id":"s2","type":"clinical_trial","url":"https://clinicaltrials.gov/","title":"STEP trial program summary","quote":"Average 15 % weight loss at 68 weeks.","summary":"Human weight-loss magnitude for semaglutide.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"d58983d7057c70e6324ca602079491f6050c346ff7815d0f87283d4a578f2845"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"pt-141-semaglutide","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":3,"anecdotal":1,"scientific":2,"user_reports":0,"questions":0,"evidence_ingests":0}}